更新于：2024-11-01
Fluocinolone Acetonide/Hydroquinone/Tretinoin
氟轻松丙酮酯/氢醌/维A酸
更新于：2024-11-01
概要
基本信息
药物类型 小分子化药 |
别名 Hydroquinone/tretinoin/fluocinolone-acetonide、Tri-Luma |
作用机制 GR激动剂(糖皮质激素受体激动剂)、RARα激动剂(维甲酸受体α激动剂)、RARβ2激动剂(维甲酸受体β激动剂) |
在研适应症 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-01-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H30F2O6 |
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N |
CAS号67-73-2 |
查看全部结构式(3)
关联
6
项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床试验多中心、随机、双盲、三臂、平行、安慰剂对照临床试验评价维氟醌乳膏治疗中、重度黄褐斑的疗效和安全性
Evaluation of â??Quality of Lifeâ?? and in-use tolerance in women with facial melasma, after using a triple combination drug (TRI-LUMA Cream)
Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的临床结果
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的转化医学
登录后查看更多信息
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的专利（医药）
登录后查看更多信息
24
项与 氟轻松丙酮酯/氢醌/维A酸 相关的文献（医药）2022-03-01Food chemistry1区 · 农林科学
The inhibition of pectin oligosaccharides on degranulation of RBL-2H3 cells from apple pectin with high hydrostatic pressure assisted enzyme treatment
1区 · 农林科学
Article
作者: Wang, Yu ; Gao, Zhenpeng ; Yue, Tianli ; Long, Fangyu ; Ma, Jing ; Ren, Hong ; Tong, Pengyan ; Chen, Yajing
The conditions for the preparation of pectic oligosaccharides (POS) by high hydrostatic pressure-assisted enzymatic (E-HHP) method were explored. The optimal conditions consisted of the pressure of 350 MPa for 20 min, and enzymolysis for 60 min with 0.011 U/mL enzyme. The products were isolated by ion exchange chromatography, galacturonic acid, di- and tri-galacturonides (Tri-GalA) with high purity were obtained. Additionally, the effects of POS on activation and degranulation of RBL-2H3 mast cells were investigated. It was found that Tri-GalA and POS could attenuate the release of β-hexosaminidase and histamine, reduce the production of IL-4 and inhibit the extracellular Ca2+ influx of RBL-2H3 cells. Notably, 150 μg/mL POS significantly alleviated the IgE-mediated allergic reaction of RBL-2H3 cells. These results indicate that POS could be used as an inhibitor in regulating mast cell-mediated allergic inflammatory responses.
2021-07-01Veterinary parasitology, regional studies and reports
Efficacy of a single administration of afoxolaner (NexGard®) or fipronil plus permethrin (Frontline® Tri-Act) against Hyalomma marginatum ticks in dogs
Article
作者: Akki, Fatima Ezzahra ; Beugnet, Fréderic ; Madder, Maxime ; Lebon, Wilfried ; Meyer, Leon
This study was conducted to assess the acaricidal efficacy of afoxolaner (NexGard®, Boehringer Ingelheim), and fipronil - permethrin (Frontline® Tri-Act, Boehringer Ingelheim) administered once to dogs experimentally infested with Hyalomma marginatum ticks. Twenty-four Beagle dogs were randomly allocated based on a pre-treatment H. marginatum infestation to an untreated control group, a NexGard® or a Frontline® Tri-Act treated groups. Treatments were administered once on Day 0 as per the products' labels. For the efficacy evaluation, dogs were experimentally infested with 30 adult H. marginatum ticks on Days -2, 7, 28 and 36. In-situ counts were performed at 48 h post-treatment on Day 2 and post-infestations on Days 9, 30 and 38. Ticks were removed and counted at 72 h post-treatment on Day 3 and after each tick infestation on Days 10, 31 and 39. The numbers of live ticks counted in the treated groups were significantly different than in the control group at all time-points (p ≤ 0.0006). The efficacy was at least 97% after 48 h, and at least 99% after 72 h for both treatments. In this study both afoxolaner and fipronil/permethrin formulations demonstrated a high efficacy against adult H. marginatum ticks in treated dogs for at least five weeks.
2020-01-01VETERINARY PARASITOLOGY
Experimental assessment of permethrin-fipronil combination in preventing Leishmania infantum transmission to dogs under natural exposures
Article
作者: Madder, Maxime ; Angelou, Athanasios ; Lebon, Wilfried ; Papadopoulos, Elias ; Beugnet, Frederic
Canine vector-borne disease transmission can be reduced with regular use of repellent insecticides. The objective of this year-long experimental study was to assess the efficacy of a topical formulation of fipronil/permethrin (Frontline Tri-Act®) in preventing transmission of Leishmania infantum by sandflies. This clinical field trial was conducted in Xanthi (Northern Greece), an area highly endemic for canine leishmaniosis, from April 2018 to March 2019. Forty purpose-bred Beagle dogs, testing negative for L. infantum prior to study initiation, were enrolled in the study, which consisted of three phases: Phase 1 (field exposure phase) took place from Day 0-196. The dogs were randomly allocated to two groups, group 1 (sham-treated topically with sterile water) and group 2 (treated topically with Frontline Tri-Act®). Dogs in both groups were housed in two subunits of an open-air kennel for a period of 7 months, spanning the Leishmania transmission season. All dogs were treated or sham-treated on Days 0, 28, 56, 84, 112, 140 and 168. Clinical examinations, PCR analysis of conjunctival swabs, and serological tests were performed on a monthly basis. Sandflies were collected every 2 weeks, during a 12 -h period overnight using light traps. Each collection was placed in a container and kept refrigerated until speciation and PCR analysis could be performed. In the second phase of the study, from Day 197 to 252, the dogs were moved into a protected environment (insect-proof protected environment phase). CDC light traps were activated every 2 weeks inside and outside the kennels to ensure the vector-free status of the facility. Monthly clinical examinations, including PCR analysis of conjunctival swabs, and serological tests continued. At the end of the phase 2, bone marrow samples were collected on all dogs. Phase 3 (the final post-winter check) took place from Day 253 to 350. Dogs were released and adopted by individual private owners on Day 253. Follow up analyses included blood collection for SNAP tests and conjunctival swaps for PCR analysis on Days 304 and 350. Additionally, bone marrow collections were also performed on Day 350. Presence of sandflies was observed only in the phase 1 exposure period, and 1714 sandflies were collected (1427 females and 287 males). Two species were identified, Phlebotomus perniciosus var. tobbi and Phlebotomus neglectus. Out of the 62 pooled samples of sandflies assessed by PCR, three were considered positive (4.8 %). By the end of the study, 35 % of the Group 1 dogs (7/20) became positive based on PCR (conjunctival swab and bone marrow) and 30 % (6/20) based on SNAP/IFAT and ELISA tests, while all the dogs in the Frontline Tri-Act® treated group 2 remained negative for all tests (G1 vs G2, p = 0.008). All tests identified the same positive animals, and PCR allowed the detection of one additional infected dog. This clinical field trial demonstrated that monthly administration of Frontline Tri-Act® to dogs exposed to Leishsmania infection in a high endemic area provided 100 % preventive efficacy against transmission of L. infantum.
100 项与 氟轻松丙酮酯/氢醌/维A酸 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黄褐斑 | 美国 | 2002-01-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 50 | Cryotherapy (CRY-AC3® device)+Tri-luma (Group 1) | 餘窪顧積憲製衊襯繭範(選遞廠衊廠鹹膚蓋淵鏇) = 觸齋齋淵鹽鹹夢獵積艱 鹽鹽齋淵顧築遞鹹範鏇 (鹽襯衊衊艱鏇範簾築鏇, 獵衊醖構壓衊獵範窪鏇 ~ 遞鏇鬱淵顧範願製糧糧) 更多 | - | 2020-09-17 | ||
Cryotherapy (CRY-AC3® device) (Group 2) | 餘窪顧積憲製衊襯繭範(選遞廠衊廠鹹膚蓋淵鏇) = 築觸鏇製廠範蓋鏇蓋廠 鹽鹽齋淵顧築遞鹹範鏇 (鹽襯衊衊艱鏇範簾築鏇, 簾壓蓋膚膚鬱餘繭窪窪 ~ 夢蓋糧繭獵鹽獵鹽繭網) 更多 | ||||||
临床4期 | 56 | (Intense Pulsed Light (IPL) / Tri-Luma® Cream) | 築衊襯廠築鹽願膚艱築(選衊淵鏇鏇築製選範構) = 積艱遞獵製壓蓋壓鑰艱 夢構齋積鬱廠積鹹鬱遞 (膚蓋築鹽鹽壓遞壓蓋構, 選壓糧鹹齋願鑰願選壓 ~ 憲糧鑰繭觸糧艱廠顧夢) 更多 | - | 2010-01-11 | ||
Cetaphil (Intense Pulsed Light (IPL) / Inactive Control Cream) | 築衊襯廠築鹽願膚艱築(選衊淵鏇鏇築製選範構) = 網衊觸獵選膚獵簾顧壓 夢構齋積鬱廠積鹹鬱遞 (膚蓋築鹽鹽壓遞壓蓋構, 範簾觸繭觸網鹽繭築襯 ~ 窪夢繭鏇觸製蓋餘選積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用